Biopharmx Corp (NYSEAMERICAN:BPMX) shares traded down 0% on Thursday . The stock traded as low as $0.18 and last traded at $0.18. 4,546,957 shares were traded during trading, a decline of 61% from the average session volume of 11,589,708 shares. The stock had previously closed at $0.18.

Separately, Maxim Group restated a “buy” rating and set a $1.50 price objective on shares of Biopharmx in a report on Friday, December 8th.

The company has a market cap of $25.50, a price-to-earnings ratio of -0.67 and a beta of 1.40.

Biopharmx (NYSEAMERICAN:BPMX) last announced its earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05).

In other news, Director Stephen Morlock bought 330,000 shares of the stock in a transaction dated Friday, November 24th. The stock was bought at an average price of $0.15 per share, for a total transaction of $49,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

ILLEGAL ACTIVITY WARNING: “Biopharmx (BPMX) Trading Down 0%” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.